MétaCan
Menu
← Back to cohort

Identifying candidates for prednisone to dexamethasone switch amongst patients with castration-resistant prostate cancer undergoing abiraterone therapy.

2016· article· en· W2890336344 on OpenAlexaffabout
Vanessa Sarah Arciero, Kelly Lien, Erica McDonald, Esther K. Lee, Phillip Blanchette, Urban Emmenegger

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsHealth Sciences CentreSunnybrook Health Science Centre
Fundersnot available
KeywordsMedicinePrednisoneProstate cancerDocetaxelDexamethasoneInternal medicineAbiraterone acetateCancerChemotherapyUrologyCorticosteroidOncologyGastroenterologyAndrogen deprivation therapy

Abstract

fetched live from OpenAlex

e16568 Background: Abiraterone plus prednisone (AA+P) delays symptomatic progression, palliates symptoms, and improves survival of pts with castration-resistant prostate cancer (CRPC). While inherent or acquired therapeutic resistance limits the benefit of AA+P, emerging data suggest that a switch from prednisone to dexamethasone (D) may achieve durable biochemical responses in CRPC pts progressing on AA+P. Methods: To better understand who may benefit from a steroid switch, we analyzed the outcome of pts switched to AA+D upon biochemical progression on AA+P, among CRPC pts treated at Sunnybrook Odette Cancer Centre, Toronto, Canada. Pts were included if they had undergone AA+D therapy (D 0.5 or 1.0 mg po daily) for at least 12 weeks. Results: 18 pts fit the inclusion criteria, of which 11 were chemotherapy-naïve, and 7 had received prior docetaxel. None had received P or D monotherapy previously. 8 pts (44%) achieved a > 50% PSA reduction with AA+P (PSA50), and 3 pts (17%) had a > 30% PSA response (PSA30). In 6 pts (33%) we found PSA stabilization (PSA-SD) as best response, whereas 1 pt (6%) biochemically progressed on AA+P. Mean (±SD) AA+P treatment duration was 213.44 (±151.24) days. Upon switch to AA+D, 5 pts (28%) achieved a PSA50, 1 pt (6%) a PSA30, PSA remained stable in 11 pts (61%), and 1 pt (6%) progressed biochemically. 6 pts are still continuing on AA+D after a median follow-up of 278 days. Amongst 11 AA+P responders (ie PSA50 or PSA30), 4 pts also achieved a sustained PSA50 on AA+D (202, 251, 399+, 587+ days), and 1 pt a PSA30 (274+). By contrast, only 1 of the 7 AA+P non-responders (14%) achieved a PSA response. Prior docetaxel did not affect the response to steroid switching. No unexpected adverse events were observed. Further data is being collected prospectively. Conclusions: In these mostly chemotherapy-naïve CRPC pts undergoing AA therapy, switching from P to D resulted in sustained PSA50 or PSA30 in 33% of pts. Whereas responses were seen in 5 of 11 pts (45%) with prior response to AA+P, the benefit of a P to D switch seems to be very limited in pts without prior response to AA+P.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.010
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.134
GPT teacher head0.472
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→